Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
基本信息
- 批准号:10544356
- 负责人:
- 金额:$ 11.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-17 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAgonistAnimalsAntifungal AgentsAntigensBindingBlastomycesC Type Lectin ReceptorsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCellsCombined VaccinesCommunicable DiseasesDevelopmentDinucleoside PhosphatesFosteringFungal VaccinesGenetic TranscriptionGoalsHumanImmunityImmunizationImmunologic ReceptorsImmunologistInfluenza A virusInhalationInterleukin-2LigandsLipid ALungMaintenanceMemoryMucous MembraneMycosesPPBP genePathway interactionsPeriodicityPolysaccharidesPrimary InfectionPublic HealthReportingResidenciesRespiratory SystemRespiratory Tract InfectionsStructure of parenchyma of lungSystemT cell responseT memory cellT-LymphocyteTLR4 geneTestingTh1 CellsTimeTissuesVaccine AdjuvantVaccinesViralViral Respiratory Tract InfectionVirusWorkbasebeta-Glucansdectin 1designfactor Cfunctional plasticityfungal pneumoniafungushuman pathogeninfluenza A virus nucleoproteininfluenzavirusinnovationinsightmemory CD4 T lymphocytemouse dectin-2nanoemulsionparenteral administrationparticlepathogenpathogenic funguspathogenic microbepathogenic virusprogramsrespiratorysingle-cell RNA sequencingsoundstem cellsstem-like cellstemnesstooltranscription factortranscriptomevaccine developmentvaccine formulation
项目摘要
ABSTRACT: Respiratory infections with viruses and fungi constitute major public health problems globally.
Except for influenza virus, there are no licensed vaccines against viruses or fungi. It is generally agreed that
induction of T-cell memory is critical for defense against viruses and fungi in the respiratory tract. We and others
have shown that induction of tissue-resident memory (TRM) CD8 and CD4 T cells and systemic migratory memory
CD4 T cells are essential for protection against influenza A virus (IAV) and inhaled fungi, respectively. However,
both TRM cells and systemic memory CD4 T cells undergo attrition, leading to short-lived immunity, which is
especially true for TC1/TH1 cells. Therefore, induction of durable T-cell immunity poses major challenges for
vaccinologists. As compared to TH1 cells, TH17 cells display sought-after attributes of stem-ness, durability and
functional plasticity. We propose to tailor combination adjuvants to harness T17 programming and induce durable
and protective lung TRM cells and migratory memory CD4 T cells against viruses and fungi.
We find that Adjuplex, a nano-emulsion adjuvant, when combined with the TLR4 agonist glucopyranosyl
lipid A (GLA), evokes antigen-specific CD8 and CD4 T-cell responses in the lung that are: (i) durable and
multifaceted (TC1/TC17/TH1/TH17), and (ii) confer heterosubtypic immunity against IAV that persists >400 days.
We further find that combining those adjuvants with fungal CLR ligands Blastomyces endoglucanase 2 (Bl-Eng2;
Dectin-2 agonist) and b-glucan particles (Dectin-1 agonist) augments antiviral TC17/TH17/TC1/TH1 and elicits
migratory memory T cells that protect against fungal pneumonia. By single-cell RNAseq, we found that our
combined adjuvants induce memory antiviral and antifungal CD8 and CD4 T-cell clusters that express ICOS
(Inducible T Cell Co-stimulator), the transcription factor c-Maf, and a transcriptome that fosters tissue residency,
stem cell-ness and non-pathogenic T17 programming. Cyclic dinucleotides also promote T17 programming in
lungs. This, we postulate that programming stem cell-like, functionally plastic, non-pathogenic TC17/TH17
memory cells with our combination adjuvants (that engage TLR-4, Dectin-1/2 and STING pathways) will foster
durable protective immunity to viral and fungal pathogens in the lung. Our specific aims will test three
hypotheses: Aim 1: Combination adjuvants that evoke TC17/TH17 stem cell-like functionally-plastic TRM or
systemic migratory memory will engender durable immunity to respiratory viral and fungal pathogens; Aim 2:
Functional plasticity of TC17/TH17 memory is important for protective immunity to viruses and fungi; Aim 3: The
ICOS/c-Maf pathway is integral to establishment and/or maintenance of durable vaccine-induced protective
immunity to respiratory viral and fungal infections. The proposed work is significant and of high impact because
it has the potential to create a tractable adjuvant system/tool kit that will advance the formulation of vaccines: (i)
targeted for mucosal or parenteral administration; (ii) designed to induce TRM or systemic T-cell memory; and (iii)
tailored to elicit CD8 and CD4 T cells that protect against diverse pathogens such as viruses and fungi.
摘要:呼吸道病毒和真菌感染是全球主要的公共卫生问题。
除流感病毒外,没有获得许可的针对病毒或真菌的疫苗。人们普遍认为
诱导T细胞记忆对于防御呼吸道中的病毒和真菌至关重要。我们和其他人
已经表明,诱导组织驻留记忆(TRM)CD8和CD4T细胞和系统性迁移记忆
CD4T细胞对于预防甲型流感病毒(IAV)和吸入性真菌分别是必不可少的。然而,
TRM细胞和系统记忆CD4T细胞都会发生磨损,导致短暂的免疫,这是
对于Tc1/TH1细胞尤其如此。因此,诱导持久的T细胞免疫对
疫苗专家。与TH1细胞相比,TH17细胞显示出干细胞特性、耐久性和
功能可塑性。我们建议量身定做组合佐剂以利用T17编程并诱导耐用性
保护肺TRM细胞和移行记忆CD4T细胞免受病毒和真菌的侵袭。
我们发现,当与TLR4激动剂葡萄糖吡喃葡萄糖联合使用时,纳米乳佐剂Adjuplex
脂质A(GLA),在肺内激发抗原特异性的CD8和CD4T细胞反应:(I)持久和
多方面(Tc1/TC17/TH1/TH17),和(Ii)提供对IAV的异型免疫,持续400天。
我们进一步发现,将这些佐剂与真菌CLR配体Blstomyces endoganase 2(Bl-Eng2;
Dectin-2激动剂)和b-葡聚糖颗粒(Dectin-1激动剂)增强抗病毒TC17/TH17/Tc1/TH1并诱导
移行记忆T细胞,可预防真菌性肺炎。通过单细胞RNAseq,我们发现我们的
联合佐剂诱导表达ICOS的记忆、抗病毒和抗真菌CD8和CD4T细胞群
(可诱导T细胞共刺激因子),转录因子c-Maf,以及促进组织驻留的转录组,
干细胞特性和非致病性T17编程。环二核苷酸也促进T17编程
肺部。这一点,我们假设,编程干细胞样的,功能可塑性的,非致病的TC17/TH17
使用我们的组合佐剂(参与TLR-4、Dectin-1/2和STING通路)的记忆细胞将促进
对肺部的病毒和真菌病原体具有持久的保护性免疫。我们的具体目标将考验三个
假设:目标1:联合佐剂可激发TC17/TH17干细胞样功能可塑性TRM或
系统性迁移记忆将产生对呼吸道病毒和真菌病原体的持久免疫力;目标2:
TC17/TH17记忆的功能可塑性对病毒和真菌的保护性免疫很重要;目标3:
ICOS/c-maf通路对于建立和/或维持疫苗诱导的持久保护性是不可或缺的
对呼吸道病毒和真菌感染具有免疫力。拟议的工作意义重大,影响很大,因为
它有可能创造一种易于处理的佐剂系统/工具包,以促进疫苗的配制:(1)
以粘膜或非肠道给药为目标的;(Ii)旨在诱导TRM或系统T细胞记忆的;以及(Iii)
量身定做,以诱导CD8和CD4T细胞,以保护免受各种病原体,如病毒和真菌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRUCE Steven KLEIN其他文献
BRUCE Steven KLEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRUCE Steven KLEIN', 18)}}的其他基金
Mechanisms of vaccine immunity against coccidioidomycosis
球孢子菌病疫苗免疫机制
- 批准号:
10584260 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
Mechanisms of Vaccine Immunity against Coccidioidomycosis
球孢子菌病疫苗免疫机制
- 批准号:
10591641 - 财政年份:2022
- 资助金额:
$ 11.79万 - 项目类别:
Lung epithelial cell regulation of immunity to inhaled fungi
肺上皮细胞对吸入真菌免疫的调节
- 批准号:
10222492 - 财政年份:2018
- 资助金额:
$ 11.79万 - 项目类别:
Lung epithelial cell regulation of immunity to inhaled fungi
肺上皮细胞对吸入真菌免疫的调节
- 批准号:
10451274 - 财政年份:2018
- 资助金额:
$ 11.79万 - 项目类别:
Lung epithelial cell regulation of immunity to inhaled fungi
肺上皮细胞对吸入真菌免疫的调节
- 批准号:
9975090 - 财政年份:2018
- 资助金额:
$ 11.79万 - 项目类别:
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
- 批准号:
10614603 - 财政年份:2016
- 资助金额:
$ 11.79万 - 项目类别:
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
- 批准号:
10224468 - 财政年份:2016
- 资助金额:
$ 11.79万 - 项目类别:
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
- 批准号:
10448406 - 财政年份:2016
- 资助金额:
$ 11.79万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 11.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 11.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 11.79万 - 项目类别:














{{item.name}}会员




